An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials
Related Articles
Reconsidering the revised amyotrophic lateral sclerosis functional rating scale for ALS clinical trials
Introduction Clinical trials in amyotrophic lateral sclerosis (ALS) aim to identify treatments that can slow functional decline or prolong survival time. In the absence of…
Metabolic brain changes across different levels of cognitive impairment in ALS: a 18F-FDG-PET study
Objective To identify the metabolic changes related to the various levels of cognitive deficits in amyotrophic lateral sclerosis (ALS) using 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET)…
Value of systematic genetic screening of patients with amyotrophic lateral sclerosis
Objective The clinical utility of routine genetic sequencing in amyotrophic lateral sclerosis (ALS) is uncertain. Our aim was to determine whether routine targeted sequencing of…
Visualization of Gray Matter Atrophy and Anterior Corticospinal Tract Signal Hyperintensity in Amyotrophic Lateral Sclerosis Using 7T MRI
Two patients with amyotrophic lateral sclerosis (ALS) presenting with different phenotypic descriptions underwent 7T MRI examination: a man with left upper limb amyotrophy due to…
Editors' Note: Phenotypic Variability in ALS-FTD and Effect on Survival
Dr. Ahmed et al. examined initial presentations and cognitive and behavioral profiles in 59 patients with amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD) and 39…
English
العربية
简体中文
Nederlands
Français
Deutsch
Italiano
Português
Русский
Español
Responses